<DOC>
	<DOCNO>NCT02057159</DOCNO>
	<brief_summary>Multi-center , randomize , double-blind , placebo-controlled , two arm parallel design study NeuroVax™ v . Incomplete Freund 's Adjuvant ( I F A ) placebo . 200 subject Secondary Progressive SPMS</brief_summary>
	<brief_title>A Study NeuroVax™ , Therapeutic TCR Peptide Vaccine SPMS Multiple Sclerosis</brief_title>
	<detailed_description>Objectives : The primary objective compare treatment group cumulative number new gadolinium enhancing ( Gd+ ) lesion brain MRI week 24 , 32 , 40 48 n subject secondary progressive MS . Secondary objective include additional MRI measurement , analyse clinical relapse , measure neurologic disability , immunologic evaluation , safety . Study Design : Multi-center , randomize , double-blind , placebo-controlled , two arm parallel design study NeuroVax™ v . Incomplete Freund 's Adjuvant ( I F A ) placebo . Subject Population : 200 subject Secondary Progressive SPMS MS , EDSS score &gt; = 3.5 , meet inclusion/exclusion criterion , enroll study . Subjects randomize equally NeuroVax™ I F A ,1 0 0 per arm .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>Subject 18 50 year age , inclusive . Definite MS revise McDonald criterion ( 2005 ) ( Appendix A ) , Secondary Progressive course . Expanded Disability Status Scale ( EDSS ) &gt; =score 3.5 ( Appendix B ) . Two document clinical relapse MS precede 24 month OR one document clinical relapse MS precede 1 2 month prior screen . Laboratory value within follow limit : Creatinine 1 . 5 x high normal . Hemoglobin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Secondary Progress Multiple Sclerosis</keyword>
	<keyword>SPMS</keyword>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>NeuroVax</keyword>
</DOC>